ArticleCancer science2019

Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.

Wei Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.